ORLANDO, Fla., Feb. 23 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the "Company" or "Telzuit") announced today that Jim Tolan, Co-Founder and SVP of Business Development of Telzuit, will be presenting at the EQUITIES Magazine Emerging Growth Stock Day XIII on Friday, February 24, 2006 at the Yale Club in New York City. Mr. Tolan is scheduled to present on February 24 at 3:00 p.m. ET. The Emerging Growth Stock Day XIII, which will be attended by more than 200 financial advisors, money managers and institutional investors, will focus on some of the leading emerging public companies in the marketplace today.
Within Telzuit's presentation, the Company will highlight its series of BioPatch medical monitoring products, including its FDA-approved BioPatch Wireless Cardiac Holter Monitor System. Targeting the $81 billion outpatient cardiac disease treatment market, The BioPatch Wireless Holter Monitor will revolutionize the way that physicians obtain ECG data for their patients by combining comfort and technology. The BioPatch system provides patients with a comfortable and unobtrusive wireless patch that lets them proceed with their everyday routine, while also allowing physicians to download full 12-lead EKG data on a real-time basis through Telzuit's state-of-the-art medical monitoring center. The BioPatch system represents an efficient and cost- effective alternative to traditional Holter monitoring.
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The first step in this mission will initially take the form of our state-of-the-art, FDA approved, Bio-Patch Wireless Heart Monitor. This is a full 12-lead, completely wireless, Holter monitor, which is new to the marketplace. Telzuit is also building its own dedicated intranet as a platform to handle several of the products it will be releasing, including its initial product, the Bio-Patch Wireless Heart Monitor. More information on Telzuit, its business model, and its products can be found on its website: http://www.telzuit.com, or by calling 407-354-1222.
Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Contacts: Telzuit Medical Technologies, Inc, Orlando James Tolan, Senior VP 407-354-1222 Brainerd Communicators, Inc. Jennifer Gery (press) Todd St. Onge (investors) 212-986-6667
Telzuit Medical Technologies, Inc.CONTACT: James Tolan, Senior VP of Telzuit Medical Technologies, Inc.,Orlando, +1-407-354-1222; Jennifer Gery (press) or Todd St. Onge(investors) both of Brainerd Communicators, Inc., +1-212-986-6667
Web site: http://www.telzuit.com/
